续用倍他乐克对心力衰竭急性发作患者的疗效研究

The Clinical Effect Study of Continued Useing Betaloc on Congestive Heart Failure Patients with Acute Exacerbation

目的:探讨心力衰竭急性发作期续用倍他乐克对心力衰竭的影响。方法:120例慢性心力衰竭急性发作患者(均长期使用倍他乐克),随机分为两组,治疗组60例,对照组60例。治疗组予常规抗心力衰竭治疗,包括应用血管紧张素转换酶抑制剂(ACEI)或血管紧张素Ⅱ受体拮抗(ARB)、利尿剂、洋地黄、硝酸酯类、醛固酮拮抗剂等,在常规综合治疗的基础上继续使用倍他乐克维持原剂量不变;对照组入院后停用倍他乐克按常规治疗,症状平稳后再次使用;两组均在治疗前及治疗1周后检测高敏C反应蛋白(hs-CRP),在治疗前及治疗1个月后检测左室射血分数值(LVEF)。结果:对照组治疗总有效率为83.3%,治疗组为90.0%,两组治疗总有效率比较差异无统计学意义(P>0.05);两组治疗后C反应蛋白较治疗前均有明显降低(P<0.01),但治疗组降低更明显,差异有统计学意义(P<0.05);两组治疗后LVEF较治疗前均有明显升高(P<0.05),但治疗后组间比较差异有统计学意义(P<0.05)。结论:在慢些心力衰竭急性发作期常规抗心力衰竭治疗基础上继续使用倍他乐克未见加重病情,而且有利于心力衰竭患者预后的改善。

Objective： To investigate the effect of betaloc on chronic heart failure with the acute exacerbation.Method： 120 cases of acute exacerbation of chronic heart failure patients（with a long-term betaloc useing）, were randomly divided into two groups, treatment group of 60 cases, 60 cases of the control group.Treatment group accepted general integrated treatment, including angiotensin converting enzyme inhibjtors or, diuretic, digitalis, nitric acid ester, aldosterone antagonist etc, and continues to using with betaloc; control group accepted general integrated treatment and suspended using with betaloe; high sensitivity c reaction protein（hs-CRP） before treatment and a week after treatment were detected in two groups; left ventricular ejection fraction（LVEF） before treatment and a month after treatment were detected in two groups.Result： The efficient rate in the treatment group was 90.0%; the total efficient fete was 83.3% in the control group; the total efficient of two groups comparison was no statistics significance（P〉0.05）; two groups of hs-CRP after treatment had decreased outstandingly（P〈0.05）, but the treatment group decreased significantly（P〈0.05）.Two groups of LVEF after treatment had improved outstandingly（P〈0.05）, but the treatment group improved significantly（P〈0.05）.Conclusion： Continued useing betaloc on congestive heart failure patients with acute episode clinical has not aggravated the condition, but also contribute to improve the prognosis of patients with heart failure.